A proposed deal to buy up a portfolio of biotechs in Neil Woodford’s collapsed investment fund has fallen through, raising the risk of a cut-price ‘fire sale’ of the stocks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,